Many Biosimilar Developers See US FDA Streamlining Positively, Some Concerned

 
• By Dave Wallace
  
The new guidance is a paradigm shift for biosimilars. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from United States